

Tecan reports key outcomes from Annual General Meeting 2025

- **Stable dividend of CHF 3.00 per share**
- **Lukas Braunschweiler, Myra Eskes, Oliver Fetzner, Matthias Gillner, Christa Kreuzburg, Monica Manotas and Daniel R. Marshak re-elected as members of the Board of Directors**
- **Lukas Braunschweiler confirmed by shareholders as Chair of the Board**
- **Myra Eskes, Christa Kreuzburg and Daniel R. Marshak confirmed as members of the Compensation Committee**
- **Shareholders approved the maximum compensation for the Board of Directors and Management Board for the next period, while the 2024 Compensation Report narrowly missed majority approval**
- **Report of non-financial matters, for the first time with an audit certificate, approved**

Männedorf, Switzerland, April 10, 2025 – The Annual General Meeting of the Tecan Group (SIX Swiss Exchange: TECN) endorsed all motions proposed by the Board of Directors. Shareholders approved the Annual Report, the financial statements and the consolidated financial statements, and granted discharge to the Board of Directors and the Management Board. They agreed to an unchanged dividend of CHF 3.00 per registered share. Half of the dividend, i.e., CHF 1.50, will be paid out from the available capital contribution reserve and is therefore not subject to withholding tax. The payout will take place on April 16, 2025.

All members of the Board of Directors proposed for re-election were confirmed by the shareholders for a term of one year: Lukas Braunschweiler, Myra Eskes, Oliver Fetzner, Matthias Gillner, Christa Kreuzburg, Monica Manotas and Daniel R. Marshak. Lukas Braunschweiler was re-elected as Chair of the Board of Directors. Karen Huebscher, who has served as a member of the Board of Directors since 2012, had decided not to stand for re-election. Lukas Braunschweiler thanked her warmly for her valuable contribution and wished her all the best for the future. The shareholders also confirmed Myra Eskes, Christa Kreuzburg and Daniel R. Marshak as members of the Compensation Committee. Myra Eskes will take over the Chair of the Compensation Committee from Christa Kreuzburg.

Other proposals

The shareholders voted on the conditions governing the compensation of the Board of Directors and Management Board for the following fiscal year. They made a binding decision to endorse the proposed maximum total amount of compensation for fiscal year 2026 and also, for the Board of Directors, for the period until the 2026 Annual General Meeting. The 2024 Compensation Report, presented for an advisory vote, narrowly missed achieving the necessary majority of the represented

votes. The Board of Directors acknowledges the low level of shareholder approval for the compensation report and is committed to reviewing the compensation framework.

For the second time, Tecan submitted a report on non-financial matters to the Company's shareholders for approval. This report underwent a limited assurance audit by Ernst & Young AG, Zurich, for the first time, focusing on key 2024 environmental and social data points. The audit certificate marks an important step in the advancement of Tecan's sustainability reporting, with additional transparency and commitment. This report was also approved by the shareholders.

Ernst & Young AG, Zurich, was reappointed as the statutory auditors for fiscal year 2025.

Shareholders approved the motion proposed by the Board of Directors to appoint Proxy Voting Services GmbH, Zurich, as the independent proxy for the period up to the close of the Tecan Group 40th Annual General Meeting in 2026.

Key upcoming dates

- A Q1 Qualitative Update will be published on May 12, 2025.
- The 2025 Interim Report will be published on August 12, 2025.
- A Q3 Qualitative Update will be published on October 13, 2025.

About Tecan

Tecan (www.tecan.com) improves people's lives and health by empowering customers to scale healthcare innovation globally from life science to the clinic. Tecan is a pioneer and global leader in laboratory automation. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments, components and medical devices that are then distributed by partner companies. Founded in Switzerland in 1980, the company has 3,300 employees, with manufacturing, research and development sites in Europe, North America and Asia, and maintains a sales and service network in over 70 countries. In 2024, Tecan generated sales of CHF 934 million (USD 1,062 million; EUR 984 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).

For further information:

Tecan Group

Martin Brändle

Senior Vice President, Corporate Communications & IR

Tel. +41 (0) 44 922 84 30

Fax +41 (0) 44 922 88 89

investor@tecan.com

www.tecan.com